Slopianka Markus, Herrmann Anne, Pavkovic Mira, Ellinger-Ziegelbauer Heidrun, Ernst Rainer, Mally Angela, Keck Matthias, Riefke Bjoern
Bayer AG, Investigational Toxicology, Muellerstraße 178, 13353 Berlin, Germany; University Wuerzburg, Department of Toxicology, Versbacher Straße 9, 97078 Wuerzburg, Germany.
Bayer AG, Investigational Toxicology, Muellerstraße 178, 13353 Berlin, Germany.
Toxicology. 2017 Jul 1;386:1-10. doi: 10.1016/j.tox.2017.05.009. Epub 2017 May 19.
Recently, bile acids (BAs) were reported as promising markers for drug-induced liver injury (DILI). BAs have been suggested to correlate with hepatocellular and hepatobiliary damage; however a clear connection of BA patterns with different types of DILI remains to be established. To investigate if BAs can improve the assessment of liver injury, 20 specific BAs were quantitatively profiled via LC-MS/MS in plasma and liver tissue in a model of methapyrilene-induced liver injury in rats. Methapyrilene, a known hepatotoxin was dosed daily over 14-days at doses of 30 and 80mg/kg, followed by a recovery phase of 10days. Conventional preclinical safety endpoints were related to BA perturbations and to hepatic gene expression profiling for a mechanistic interpretation of effects. Histopathological signs of hepatocellular and hepatobiliary damage with significant changes of clinical chemistry markers were accompanied by significantly increased levels of indivdual BAs in plasma and liver tissue. BA perturbations were already evident at the earliest time point after 30mg/kg treatment, and thereby indicating better sensitivity than clinical chemistry parameters. Furthermore, the latter markers suggested recovery of liver injury, whereas BA levels in plasma and liver remained significantly elevated during the recovery phase, in line with persistent histopathological findings of bile duct hyperplasia (BDH) and bile pigment deposition. Gene expression profiling revealed downregulation of genes involved in BA synthesis (AMACR, BAAT, ACOX2) and hepatocellular uptake (NTCP, OATs), and upregulation for efflux transporters (MRP2, MRP4), suggesting an adaptive hepatocellular protection mechanism against cytotoxic bile acid accumulation. In summary, our data suggests that specific BAs with high reliability such as cholic acid (CA) and chenodeoxycholic acid (CDCA) followed by glycocholic acid (GCA), taurocholic acid (TCA) and deoxycholic acid (DCA) can serve as additional biomarkers for hepatocellular/hepatobiliary damage in the liver in rat toxicity studies.
最近,胆汁酸(BAs)被报道为药物性肝损伤(DILI)的潜在标志物。胆汁酸已被认为与肝细胞和肝胆损伤相关;然而,胆汁酸模式与不同类型DILI之间的明确联系仍有待确立。为了研究胆汁酸是否能改善肝损伤评估,在大鼠甲氧苄啶诱导的肝损伤模型中,通过液相色谱-串联质谱法(LC-MS/MS)对血浆和肝组织中的20种特定胆汁酸进行了定量分析。甲氧苄啶是一种已知的肝毒素,每天以30和80mg/kg的剂量给药14天,随后是10天的恢复期。传统的临床前安全终点与胆汁酸扰动以及肝脏基因表达谱相关,以便对作用进行机制解释。肝细胞和肝胆损伤的组织病理学迹象以及临床化学标志物的显著变化伴随着血浆和肝组织中个别胆汁酸水平的显著升高。在30mg/kg治疗后的最早时间点,胆汁酸扰动就已明显,从而表明其比临床化学参数具有更高的敏感性。此外,后者的标志物表明肝损伤有所恢复,而血浆和肝脏中的胆汁酸水平在恢复期仍显著升高,这与胆管增生(BDH)和胆色素沉积的持续组织病理学发现一致。基因表达谱显示参与胆汁酸合成(AMACR, BAAT, ACOX2)和肝细胞摄取(NTCP, OATs)的基因下调,而外排转运蛋白(MRP2, MRP4)上调,提示肝细胞针对细胞毒性胆汁酸积累的适应性保护机制。总之,我们的数据表明,胆酸(CA)、鹅去氧胆酸(CDCA)、甘氨胆酸(GCA)、牛磺胆酸(TCA)和脱氧胆酸(DCA)等具有高可靠性的特定胆汁酸可作为大鼠毒性研究中肝细胞/肝胆损伤的额外生物标志物。